Scientists probe immune System's response to new bladder cancer drug combo
NCT ID NCT03978624
Summary
This study aims to understand how two drugs, pembrolizumab and entinostat, affect the immune system and tumor biology in patients with muscle-invasive bladder cancer. It involves 20 patients who cannot receive standard chemotherapy and are scheduled for surgery. Researchers will analyze tumor and blood samples taken before and after a short course of treatment to measure changes in immune markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.